ArticleReproductive sciences (Thousand Oaks, Calif.)2026
TRIP10 as a Key Regulator in Fetal Growth Restriction: a Study Integrating Bioinformatics Screening with Experimental Validation.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fetal growth restriction (FGR) is a leading cause of perinatal mortality, yet its molecular mechanisms remain poorly understood. This study integrated bioinformatic analysis with experimental validation to identify key genes involved in FGR pathogenesis. Transcriptome datasets GSE114691 and GSE24129 from the GEO database were analyzed, revealing 5,788 differentially expressed genes (1,450 upregulated, 4,338 downregulated) between FGR and control placental samples. Functional enrichment analysis indicated that downregulated genes were primarily involved in mitochondrial function, aerobic respiration, and amino acid metabolism, while upregulated genes were associated with cell adhesion and histone modification. Weighted gene co-expression network analysis (WGCNA) identified 19 modules, with the darkorange module showing the strongest positive correlation with FGR. LASSO regression further selected eight candidate genes, among which only TRIP10 demonstrated consistent and significant upregulation in the independent validation dataset and exhibited excellent diagnostic performance (AUC = 0.906). Western blot confirmed significant upregulation of TRIP10 protein in FGR placental tissues. Functional assays in JEG-3 trophoblast cells revealed that TRIP10 knockdown significantly enhanced cell migration and invasion, while TRIP10 overexpression suppressed these processes. Collectively, this study identifies TRIP10 as a key gene significantly upregulated in FGR placentas and establishes TRIP10 as a negative regulator of trophoblast migration and invasion, suggesting that TRIP10 dysregulation may contribute to impaired placental development and FGR pathogenesis, representing a promising biomarker and potential therapeutic target.
Indexed as
Identifiers
42823564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.